Key Points• In human aggressive B-NHLs, HSPH1 favors c-Myc and Bcl-6 expression, and its inhibition provides significant antilymphoma activity.• HSPH1 is expressed in function of Bcl-6 and c-Myc and constitutes a valuable alternative lymphoma therapeutic target of aggressive B-NHLs.We have shown that human B-cell non-Hodgkin lymphomas (B-NHLs) express heat shock protein (HSP)H1/105 in function of their aggressiveness. Here, we now clarify its role as a functional B-NHL target by testing the hypothesis that it promotes the stabilization of key lymphoma oncoproteins. HSPH1 silencing in 4 models of aggressive B-NHLs was paralleled by Bcl-6 and c-Myc downregulation. In vitro and in vivo analysis of HSPH1-silenced Namalwa cells showed that this effect was associated with a significant growth delay and the loss of tumorigenicity when 10 4 cells were injected into mice. Interestingly, we found that HSPH1 physically interacts with c-Myc and Bcl-6 in both Namalwa cells and primary aggressive B-NHLs. Accordingly, expression of HSPH1 and either c-Myc or Bcl-6 positively correlated in these diseases. Our study indicates that HSPH1 concurrently favors the expression of 2 key lymphoma oncoproteins, thus confirming its candidacy as a valuable therapeutic target of aggressive B-NHLs. (Blood. 2015;125(11):1768-1771 IntroductionWe have recently demonstrated that heat shock protein (HSP)H1/ 105 is a novel antigen and potential therapeutic target of B-cell nonHodgkin lymphomas (B-NHLs). We showed that it is expressed in function of B-NHL aggressiveness, and its targeting by a specific antibody (Ab) provides significant therapeutic activity against human aggressive B-NHLs in vivo. 1 We have now set out to clarify its role as a potential molecular target in these diseases.High-grade B-NHLs-including diffuse large B-cell lymphoma (DLBCL) with its numerous subtypes, and Burkitt lymphoma (BL)-account for ;60% of NHL cases.2 Despite their high response rate to anti-CD20 rituximab-based chemoimmunotherapy, alternative strategies are required to manage relapse and resistance, which still pose a very high risk of death in approximately one-third of cases.3 Sustained expression of Bcl-6 or c-Myc oncoprotein is the best-recognized trait of DLBCL 4 or BL, 5 respectively, whereas their concurrent overexpression defines a subset of aggressive B-NHLs with an extremely unfavorable prognosis.6 Although these transcription factors (TFs) have long been regarded as reliable lymphoma targets, 7,8 their selective inhibition has proven challenging. To ensure constitutive high expression of key oncoproteins, NHLs have shown to upregulate HSP90 and HSP70, 9,10 which assist protein folding and prevent protein degradation.11 Investigation of HSP90 inhibitors has thus been extended to lymphoma patients.
12Here we provide evidence that HSPH1 constitutes a viable alternative therapeutic target of aggressive B-NHLs insofar as the in vitro and in vivo antilymphoma activity determined by its knockdown is strongly associated with both Bcl-6 and c-Myc downmodulation...